Innoveren Scientific Inc. (IVRN)
| Market Cap | 8.00 |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.26M |
| Shares Out | 8.01M |
| EPS (ttm) | -5.51 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,085 |
| Average Volume | 16,928 |
| Open | 0.0000 |
| Previous Close | 0.0002 |
| Day's Range | 0.0000 - 0.0001 |
| 52-Week Range | n/a |
| Beta | 556.62 |
| RSI | 33.69 |
| Earnings Date | Aug 12, 2025 |
About Innoveren Scientific
Innoveren Scientific Inc., a medical bioscience company that develops technology in regenerative medicine for limb salvage. It is also developing immunotherapies for ovarian cancer, pancreatic cancer, and mesothelioma. The company was formerly known as H-CYTE, Inc. and changed its name to Innoveren Scientific Inc. in July 2023. The company is headquartered in Tampa, Florida. [Read more]
Financial Performance
In 2022, Innoveren Scientific's revenue was $453,460, a decrease of -71.86% compared to the previous year's $1.61 million. Losses were -$10.30 million, 114.6% more than in 2021.
Financial StatementsNews
Innoveren Scientific Announces 510(k) Submission for SkinDisc(TM) Lite
First Commercial Product Submission from Company's Robust Regenerative Medicine-Based Pipeline CINCINNATI, OH / ACCESSWIRE / March 6, 2024 / Innoveren Scientific Inc. (OTCQB:IVRN) ("Innoveren" or the ...
Innoveren Scientific Divests Device & Receives Capital Infusion
Proceeds to be used to complete corporate rebranding, accelerate acquisition pipeline, and attract additional investment TAMPA, FL / ACCESSWIRE / October 3, 2023 / Innoveren Scientific Inc. (OTCQB:IVR...